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Abstract 
 
In the absence of validated and regulatory accepted alternative methods, the assessment of the skin sensitisation potential of 
chemicals still relies on animal testing. Progress in the development of alternative methods has been prompted by the increasing 
knowledge on the key mechanisms of the skin sensitisation pathway, as recently documented in the OECD Adverse Outcome 
Pathway for skin sensitisation. Based on an analysis of the regulatory requirements for this endpoint within relevant pieces of EU 
chemicals legislation, EURL ECVAM has decided to focus its efforts on the development of non-animal testing strategies for 
skin sensitisation hazard identification and classification, including the subcategorisation of sensitisers, according to the GHS 
classification system. This would satisfy the majority of the regulatory requirements within the EU and would have a significant 
impact in terms of replacing animal experiments. This report describes the EURL ECVAM strategy for achieving this goal. 
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1. Executive Summary 
 
The identification of chemicals that have the potential to induce skin sensitisation is 
currently based on the use of animal tests since there are no regulatory accepted alternative 
(non-animal) methods for this purpose. Despite the mechanistic complexity of the 
endpoint, important advances in the development of alternative methods have been made 
in recent times due to the good understanding of the chemistry and biology underlying this 
toxicological effect, as documented in the Adverse Outcome Pathway (AOP) for skin 
sensitisation developed by the OECD. This progress is reflected in the numerous 
submissions of alternative test methods for skin sensitisation that EURL ECVAM has 
received. 
 
In order to define its own strategy for advancing in the field and for having a framework 
for the prioritisation of submitted test methods, EURL ECVAM performed an assessment 
of the regulatory needs for this endpoint within pieces of EU legislation where the 
generation of skin sensitisation information represents a standard requirement, i.e. the 
Classification Labelling and Packaging of substances and mixtures (CLP) Regulation  in 
its current form and expected revision, the REACH Regulation, the Plant Protection 
Products (PPP) Regulation, the Biocides Directive and the Cosmetics Directive. 
 
From this analysis it became evident that in order to satisfy all regulatory needs, 
information on skin sensitisation potency would also be needed. The availability of 
alternative methods that in isolation or in combination will be able to characterise the 
potency of a sensitiser would lead to the full replacement of testing on animals for this 
endpoint. Nevertheless, having non-animal approaches capable of identifying skin 
sensitisation hazard and generating information that would satisfy classification needs (i.e. 
GHS sub-categorisation) would have the biggest impact on the saving of animals for 
regulatory testing in the short and medium term.  
 
In the light of this, EURL ECVAM has decided to focus its efforts in the skin sensitisation 
area for the next five years on the development of non-animal testing strategies suitable 
for the hazard identification and sub-categorisation of sensitisers. EURL ECVAM will 
also play a leading role within the OECD to develop a set of complementary Test 
Guidelines and related guidance documentation that will facilitate a globally accepted 
approach for skin sensitisation hazard identification and classification.  
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2. Introduction 
 
Skin sensitisation resulting in Allergic Contact Dermatitis (ACD) is the outcome of a 
number of complex interactions at molecular, cellular and tissue levels. It is a delayed-type 
hypersensitivity reaction typically induced by low molecular weight reactive chemicals. It 
develops in two distinct phases, the induction phase, which sensitises the immune system 
for an allergic response, and the elicitation phase which occurs following a subsequent 
contact with the allergen and which leads to the clinical symptoms.  
 
Presently the identification of chemicals that have the potential to induce skin sensitisation 
is based on the use of animal tests since there are no regulatory accepted alternative 
methods for this purpose (see Annex). However, despite the complexity of the endpoint, 
important advances in the development of alternative methods have been made due to the 
extensive research efforts within both industry and academia. This activity is reflected in 
the numerous submissions of test methods that EURL ECVAM has received in recent 
times.  
 
Alternative approaches currently under development and evaluation are designed to 
address and model the key biological mechanisms of the induction phase of skin 
sensitisation. These include: 1) the ability of the chemical to penetrate the skin and reach 
the site of haptenation (skin bioavailability), 2) the covalent binding of the chemical to the 
skin protein (haptenation), 3) the release of pro-inflammatory signals by epidermal 
keratinocytes, 4) the activation and maturation of dendritic cells (DC), the skin immuno-
competent cells, 5) the migration of DC from skin to the regional lymph nodes and 
presentation of the antigen to T cells, 6) the proliferation of memory T cells (lymphocytes 
capable of being stimulated and activated specifically by the haptenated protein) (Adler et 
al. 2011).  
 
Recently the Organisation for Economic Co-operation and Development (OECD) has 
developed and endorsed an Adverse Outcome Pathway (AOP) specifically for skin 
sensitisation (OECD 2012a, OECD 2012b). The AOP describes in detail the key 
biological events or mechanisms underlying skin sensitisation starting from the molecular 
initiating event (covalent binding of a chemical to skin proteins) through to adverse health 
effects in humans. Making the collective knowledge on the skin sensitisation process 
explicit in this way provides an invaluable theoretical and regulatory framework to guide 
method development, integration and validation.  
 
Moreover, since the AOP comprises a number of key events that must occur before skin 
sensitisation manifests itself, it is generally accepted that a combination of methods, either 
in vitro, in chemico or in silico, will be necessary to deliver solutions for achieving full 
replacement of in vivo tests for both hazard identification and risk assessment. However, 
despite the fact that the AOP and associated key events are well known, it is not yet clear 
which events or mechanisms are the main determinants of the potency of an allergen. As a 
consequence, definitive Integrated Testing Strategies (ITS) for potency prediction have yet 
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to be developed. Considerable progress has been made in the area of hazard identification 
and thus it is realistic to consider this an achievable goal in the medium term. However, 
delivering solutions that would satisfy the needs of a full quantitative risk assessment for 
skin sensitisation, where a more precise prediction of potency is required, remains a 
challenge. 
 
The purpose of this document is to describe the EURL ECVAM strategy for full 
replacement of animal testing for skin sensitisation hazard identification and classification 
(i.e. with the ability to discriminate between sensitisers and non-sensitisers and to 
subcategorise sensitisers according to the two GHS subcategories 1A and 1B). The 
ultimate aim of the EURL ECVAM strategy is to propose solutions that can satisfy 
information requirements under EU chemicals legislation, and that can also be considered 
by the OECD in the context of a globally harmonised approach for skin sensitisation 
hazard identification and classification.  
 
3. Satisfying Regulatory Needs without the Use of Animals 
 
Considering the information requirements for skin sensitisation within relevant regulations 
in the EU (see Annex), it is clear that potency information is needed in order to fulfil all 
the regulatory needs. A good understanding of skin sensitiser potency is particularly 
important for the safety assessment of cosmetics ingredients where this information is 
used in combination with information on the expected human exposure to predict the risk 
for human health and for establishing safe levels of exposure to such ingredients.  
 
The availability of alternative methods that in isolation or in combination will be able to 
characterise the potency of a sensitiser would lead to the full replacement of animal 
testing. However, generating hazard information (identification of the sensitisation 
potential of substances) with non-animal approaches would be sufficient to fulfil the 
requirements of important pieces of legislation, i.e. the Classification Labelling and 
Packaging of substances and mixtures (CLP) Regulation (EC 2008) in its current form, the 
REACH Regulation (EC 2006), the Plant Protection Products (PPP) Regulation (EC 
2009a) and the Biocides Directive (EC 1998), which would have a considerable impact in 
terms of animal savings. Moreover, since the risk assessment process requiring potency 
information is conducted only for those chemicals for which a sensitising hazard has been 
identified, the availability of alternative methods able to identify non-sensitising chemicals 
with a sufficient level of accuracy would also contribute to meeting the safety assessment 
requirements of the Cosmetics Regulation (EC 2009b).  
 
It is foreseen that the 2013 revision of the CLP Regulation will implement the two 
subcategories 1A “strong sensitisers” and 1B “other skin sensitisers", as adopted in the 3rd 
revised version of the Globally Harmonised System of Classification and Labelling of 
Chemicals (GHS) (UN 2011). This in turn may also affect the REACH regulation since 
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the classification according to the CLP is mandatory for registration of a substance under 
REACH. 
 
In the light of this, the availability of non-animal methods able to discriminate between 
sensitisers and non sensitisers and with the capacity to provide insights as to whether or 
not a sensitiser is a strong sensitiser (sub-category 1A of the GHS) would have the biggest 
impact in terms of saving of animals for regulatory testing in the short and medium term. 
 
Specifically, in relation to the registration deadlines of the REACH Regulation, the 
availability of reliable alternative methods able to provide mechanistic insight could 
already be used in a weight-of-evidence approach to fulfil the information requirements 
for the 2013 deadline, where assessment of skin sensitisation potential will be needed for 
approximately 1,000 substances. Regarding the 2018 REACH deadline, ITS for hazard 
identification, with the ability to assign skin sensitisers to one of the two GHS sub-
categories with sufficient accuracy, could potentially fulfil the information requirements 
for about 10,000 substances. Assuming that at least 20 animals per chemical (3 dose 
groups, 1 vehicle control group, 1 positive control group, 4 animals/group) would be 
needed for generating such information with the Local Lymph Node Assay (LLNA) (TG 
429) (OECD 2010), which is the preferred test method under REACH, the ability to 
generate such information with alternative non-animal approaches could lead to the saving 
of at least 200,000 mice. 
 
The current EURL ECVAM skin sensitisation validation study concerning the assessment 
of the reliability (i.e. transferability, within- and between-laboratory reproducibility) of 
test methods for skin sensitisation (i.e. Direct Peptide Reactivity Assay (DPRA), human-
Cell Line Activation Test (h-CLAT) is at an advanced stage, as is the assessment of 
KeratinoSens, a test methods which underwent external (non-ECVAM coordinated) 
validation. So far it appears that a number of the methods (i.e. DPRA, KeratinoSens and h-
CLAT) are adequately reproducible to be considered for inclusion in an ITS for hazard 
identification. In addition, there are already published studies describing how these 
methods can be employed in combination to increase the accuracy of prediction of skin 
sensitisation hazard when compared to the performance of individual methods (Natsch et 
al., 2009; Jaworska et al., 2011; Bauch et al., 2012; Nukada et al., 2012).  
 
Using the results of the ECVAM validation study, consideration is also being given to how 
these methods can contribute to decisions regarding sub-categorisation of skin sensitising 
chemicals (i.e. sub-category 1A and sub-category 1B of the GHS). A complementary 
project is being pursued by the Cosmetics Europe Skin Tolerance Task Force to evaluate 
how a larger set of in vitro test methods for skin sensitisation can contribute to the 
generation of potency information. 
 
The OECD has already expressed interest in in vitro methods for skin sensitisation by 
including some of them (i.e. DPRA and KeratinoSens) in its 2012 work program. In the 
third quarter of 2012 the European Commission/EURL ECVAM jointly with the Japanese 
Center for the Validation of Alternative Methods (JaCVAM) submitted a Standard Project 
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Submission Form (SPSF) to the OECD Test Guidelines Programme for the development 
of a Test Guideline for the h-CLAT.  
4. EURL ECVAM Strategy 
 
EURL ECVAM will focus its efforts on developing one or more ITS for the full 
replacement of animal testing for skin sensitisation hazard identification and classification 
(i.e. with the ability to discriminate between sensitisers and non-sensitisers and to 
subcategorise sensitisers according to the GHS). The intention is to demonstrate that these 
ITS are adequate to satisfy the information requirements of EU chemicals legislation, in 
particular CLP (i.e. GHS classification and subcategorisation), REACH, PPP and 
Biocides. In addition, the European Commission/EURL ECVAM will take a leading role 
within the OECD, the ultimate aim of which is to develop a set of complementary Test 
Guidelines and related Guidance Documents that will facilitate a globally accepted 
approach for skin sensitisation hazard identification. To achieve this, EURL ECVAM will 
pursue the following short, medium and long term goals (Figure 1). 
4.1. Short term goals (2013-2014) 
 
To exploit the methods currently undergoing formal evaluation, EURL ECVAM will:  
 
 Finalise the validation and ECVAM Scientific Advisory Committee (ESAC) peer 
review of the test methods currently under evaluation (DPRA, h-CLAT, and 
KeratinoSens) and, contingent upon the outcome of the peer-review, support the 
OECD activities for the development of Test Guidelines for these methods.  
 Take leadership at the OECD for the development of AOP-based ITS/Integrated 
Approaches to Testing and Assessment (IATA) for skin sensitisation. It is foreseen 
that this programme will be under the responsibility of the Hazard Assessment 
Task Force (HATF) and will be carried out in close cooperation with the Extended 
Advisory Group (EAG) on Molecular Screening and Toxicogenomics.  
 Explore the user requirements for an EURL ECVAM database on skin 
sensitisation, to be developed in cooperation with various collaboration partners 
and stakeholders. This would include data generated by the methods undergoing 
formal evaluation by EURL ECVAM but would not be limited to these. Further 
population of the database may be based on a public call for in vitro/in vivo data. 
 Initiate an in-house project aimed at the evaluation of method combinations (in 
silico, in chemico and in vitro) for hazard identification and classification. It is 
anticipated that as final outcome of this project multiple ITS will be developed, 
based on different user requirements. The development of ITS will take into 
consideration method combinations already proposed and in use by some 
companies. 
 Start discussions about the process for implementing future ITS in the EU 
legislation and at OECD level. 
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4.2. Medium term goals (2014-2015) 
 
The medium term goals, focusing on the improvement of a preliminary ITS approach, 
are to: 
 Identify gaps and make recommendations for further studies to generate relevant 
data to improve the predictive capacity and expand the applicability of ITS. 
 Evaluate the need to include in the ITS information on epidermal disposition and 
dermal metabolism (including, for example, information generated by QSARs, 
artificial membrane barriers, and in vitro methods).  
 Investigate the potential of mechanistic QSARs for predicting key events along the 
skin sensitisation pathway, with a view to integrating such models in the ITS. 
 
4.3. Long term goals (2016 and beyond) 
 
The long term goals, focusing on regulatory acceptance and implementation, are to: 
 
 Propose scientific solutions (ITS) based on combinations of alternative methods 
for the prediction of skin sensitisation potential and for classification purposes, 
with a view to fully satisfying regulatory information requirements in the EU (e.g. 
CLP and REACH). 
 
 Take a leading role in OECD activities on the development of Test Guidelines and 
guidance documentation, in order to facilitate a globally harmonised approach to 
the identification and classification of chemicals based on skin sensitisation 
potential. 
 
 Collaborate with partners working towards scientific solutions (ITS) for potency 
assessment, to facilitate quantitative safety assessments for the skin sensitisation 
endpoint.  
 
Figure 1: EURL ECVAM roadmap for achieving skin sensitisation hazard identification 
and classification based on alternative methods.  
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5. Evaluation of Test Methods Submitted to EURL ECVAM 
 
EURL ECVAM will continue evaluating submitted test methods in the light of its overall 
strategy. Therefore the assessment of incoming submissions will be primarily based on the 
value of information derived from these methods with respect to the methods currently 
under evaluation. In addition, new methods that provide equivalent information will also 
be considered in terms of possible advantages concerning ease of use, cost, throughput and 
widespread availability. In order to facilitate the comparison and evaluation of submitted 
test methods, EURL ECVAM may request test submitters to provide data on a specific set 
of reference chemicals (e.g. including those from the current EURL ECVAM validation 
study). Such data will likely be included in the EURL ECVAM skin sensitisation database 
serving as input to ITS development.  
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Annex. Regulatory Requirements for Skin Sensitisation 
 
1. Regulatory Requirements 
 
Information on the skin sensitisation potential of substances represents an important 
requirement in the context of several pieces of EU legislations aiming at the protection of 
human health and the environment as summarised in Table 1. The following section 
illustrates the information requirements for skin sensitisation within the regulations 
considered for the purpose of this report. 
 
1.1. Classification Labelling and Packaging 
 
The CLP Regulation (EC) No 1272/2008 for "Classification, Labelling and Packaging 
of substances and mixtures" (EC 2008) ensures that the hazards presented by chemicals 
are clearly communicated to workers and consumers in the European Union through 
appropriate hazard symbols (pictograms) and labelling phrases. The CLP Regulation 
entered into force in January 2009, and the method of classifying and labelling chemicals 
is based on the United Nations’ Globally Harmonised System (GHS) (UN 2011). The CLP 
Regulation replaces two pieces of EU legislation, the Dangerous Substances Directive and 
the Dangerous Preparations Directive and for this a transition period until 2015 is 
foreseen. 
 
Currently, the CLP Regulation allows classification of skin sensitisers in one hazard 
category (Category 1) on the basis of existing evidence in humans that the substance can 
lead to sensitisation by skin contact in a substantial number of persons or if there are 
positive results from an appropriate animal test. Since it is possible to refine the evaluation 
of the skin sensitisers on the basis of the potency of the sensitising effect, guidance is 
provided on how to evaluate the potency on the basis of the recommended test methods. 
However, classification of sensitisers into potency categories is currently not a 
requirement in the CLP, rather it is used to set specific concentration limits for chemicals, 
classified as skin sensitisers constitued in mixtures. Classification based on potency 
consideration is expected to be introduced in a future amendment of CLP (most probably 
already in 2013) for complete implementation of GHS.  
Within the GHS, skin sensitisers can be assigned to subcategory 1A “strong sensitisers” or 
to subcategory 1B “other skin sensitisers” using a weight of evidence approach on the 
basis of reliable and good quality evidence from human cases or epidemiological studies 
and/or observations from appropriate studies in recognised and officially accepted animal 
tests. 
 
1.2. Chemicals subject to REACH 
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The CLP Regulation and the REACH Regulation (EC) No 1907/2006 concerning the 
Registration, Evaluation, Authorization and Restriction of Chemicals (EC 2006a) are 
closely interlinked since the classification of a substance is a mandatory part of the 
REACH registration process. 
 
REACH applies to all chemical substances, both those used in industrial processes and 
those contained in consumer products. To comply with the Regulation, companies must 
identify and communicate the risk management measures to the users for the substances 
they manufacture and market in the EU.  
 
The REACH Regulation specifies the information that shall be submitted to ECHA for 
registration and evaluation purposes. The assessment of the skin sensitisation potential of 
substances is among the standard information requirements for substances manufactured 
or imported in the EU in quantities of one tonne or more. (Annex VII of the REACH 
Regulation). Therefore, information on skin sensitisation is a mandatory requirement for 
substances produced or imported with the lowest tonnage level, affecting all chemicals 
registered under REACH. The assessment of this endpoint comprises two consecutive 
steps: firstly an assessment of the available human, animal and alternative data and 
secondly in vivo testing.  
 
Animal testing does not need to be conducted in case there is available information to 
classify the substance for skin sensitisation or corrosivity, in case the substance is a strong 
acid or base, or in case the substance is flammable at room temperature. The Local Lymph 
Node Assay (LLNA: OECD 2010a) is the first choice method for in vivo testing. The use 
of other in vivo methods is accepted, although their use shall be scientifically justified. 
 
The precondition within REACH is that before any new in vivo tests are carried out to 
fulfil the information requirements, all available in vitro data, in vivo data, historical 
human data, data from valid (Q)SARs and data from structurally related substances (read-
across or categories) shall be assessed first, as described in the general rules for adaptation 
of the standard testing regime (Annex XI of the REACH Regulation). 
 
Under REACH, manufacturers, importers and downstream users should ensure that they 
manufacture, place on the market or use substances in such a way that they do not 
adversely affect human health. REACH Annex I describes how manufacturers and 
importers have to assess and document that the risks arising from the substance they 
manufacture or import are controlled during manufacture and their own use(s) and that 
others further down the supply chain can control the risks. REACH (Annex I, 1.0.1) 
defines the Derived No-Effect Level (DNEL), i.e. the level of exposure above which 
humans should not be exposed. In the risk characterisation, the exposure of each human 
population known to be or likely to be exposed is compared with the appropriate DNEL. 
The risk to humans can be considered to be controlled if the exposure levels estimated do 
not exceed the appropriate DNEL. 
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Skin sensitisation is generally regarded as a threshold effect, although in practice it may be 
very difficult to derive a threshold value and to set a DNEL. Normally only a qualitative 
assessment can be performed, however, the human data and data derived from the LLNA 
may be in some cases used in a more quantitative manner.  
 
Thus, the general approach to sensitizers could be viewed as a two-step procedure 
involving: 
 
a) A qualitative approach (through potency categorization) to define the Risk 
Management Measures (RMMs) and Operational Conditions (OCs).  
 
b) Where possible, by derivation of a DNEL to judge the remaining/residual 
likelihood of risks after these RMMs and OCs are implemented.  
 
RMMs and OCs may be chosen in relation to the potency of the sensitizer. The more 
potent sensitizer, the more stringent measures to control exposure are required. 
 
To provide practical guidance for the qualitative approach a hierarchy/categories of hazard 
(high, moderate and low) is proposed (ECHA, 2008). In cases where the available data 
does not allow potency categorisation of a sensitising substance, the RMMs and OCs 
applicable to the highest hazard category should be summarised. 
 
In summary, skin sensitisation potency information does not represent a legal requirement 
within REACH, however, if such information can be obtained from the data available it 
can be used to refine the risk assessment performed by manufactures/importers. 
 
REACH requires all companies manufacturing or placing a substance on the EU market in 
quantities greater than one tonne per year to register that substance with ECHA. The 
deadline of REACH registration depends on the tonnage band of a substance. The 31 May 
2013 is the deadline for industry to register all phase-in substances manufactured or 
imported in the EU at or above 100 tonnes per year. The number of phase-in substances 
(produced or imported with volumes of over 100 tonnes per year) intended to be registered 
by 31 May 2013 is assumed to be approximately 3551 (ECHA website 
http://echa.europa.eu/web/guest/reach-2013). From this number one can exclude 866 
substances already registered for the 2010 deadline (>1,000 tonnes per year) leaving 2685 
substances still to be registered by 2013. According to a report prepared by the former 
European Chemicals Bureau it was estimated that skin sensitisation test is the test that 
needs to be conducted for the highest percentage (35%) of the phase-in substances (Figure 
2). On the basis of this assumption, about 1,000 of the 2,685 substances will require 
information on their skin sensitisation potential.  
 
Phase-in substances manufactured or imported in volumes of over 1 tonne per year will 
need to be registered by the 31st May 2018. It is estimated that for approximately 20,000 
chemicals skin sensitisation information will be required. Assuming that grouping/read-
across may reduce this testing requirement by up to 50%, still about 10,000 chemicals will 
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have to be tested for skin sensitisation using animal tests unless alternative test methods 
becomes available in the meantime.  
 
Figure 2: Estimated percentage of the total number of phase-in substances that will need 
to be tested for the different endpoints under REACH (Van der Jagt et al. 2004). 
 
 
 
1.3. Plant Protection Products 
 
Regulation (EC) No 1107/2009 concerning the placing of plant protection products 
(PPP) on the market (EC 2009a) replaces Council Directive 91/414/EEC. Under the new 
PPP regulation data requirement for active substances and pesticide products are laid 
down in two separate regulations namely Regulation (EU) No 544/2011 implementing 
Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards 
the data requirements for active substances (EU 2011a) and PPP Regulation (EC) No 
545/2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of 
the Council as regards the data requirements for plant protection products (PPP) (EU 
2011b). 
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In the context of the PPP Regulation information on the skin sensitisation potential is 
mandatory for both the active substances contained in plant protection product and the 
final product. Testing for skin sensitisation of both the active substance(s) and the final 
product does not need to be conducted if the active substance or co-formulants are known 
to have sensitising properties. If sensitisation information from a valid test is not provided 
the dossier is incomplete. Skin sensitisation potency information does not constitute a 
regulatory requirement for this piece of legislation since the endpoint is not considered for 
risk assessment purposes (EC 2006b).Product 
 
1.4. Biocides 
 
Directive 98/8/EC concerning the placing of biocidal products on the market (EC 1998) 
regulates the placing of biocidal products (any substance or mixture, in the form in which 
it is supplied to the user, consisting of, containing or generating one or more active 
substances, with the intention of destroying, deterring, rendering harmless, preventing the 
action of, or otherwise exerting a controlling effect on, any harmful organism by any 
means other than mere physical or mechanical action) on the EU market. It sets out a 
Community harmonised system for the authorisation and placing on the market of biocidal 
products; for the mutual recognition of these authorisations within the Community; and for 
the establishment at Community level of a positive list of active substances which may be 
used in biocidal products. It aims to ensure a high level of protection for human and 
animal health and for the environment. Directive 98/8/EC will be replaced by Regulation 
(EU) No 528/2012 (EU 2012) concerning the making available on the market and use of 
biocidal products, which will enter into force on 1 September 2013. A technical guidance 
document in support of the implementation of the new directive is currently under 
preparation.  
 
According to the “Technical Guidance Document in Support of the Directive 98/8/EC 
concerning the placing of biocidal products on the market” and laying down the data 
requirements for active substances and biocidal product, skin sensitisation hazard 
information belong to the core data set being, therefore, mandatory for both the active 
substance and the final product. As for the PPP Regulation, potency information does not 
constitute a regulatory requirement. According to the current draft of the technical 
guidance document being prepared in support of the new regulation probably no 
substantial changes will be made to the information requirements for skin sensitisation. 
 
1.5. Cosmetics 
 
Article 2 of Council Directive 76/768/EEC on the approximation of the laws of the 
Member States relating to cosmetic products (EU 1976) specifies that a cosmetic product 
must not cause damage to human health when applied under normal or reasonably 
foreseeable conditions of use. The responsibility to demonstrate that the product is safe 
under the expected exposure conditions lies with the cosmetic manufacturer or his 
authorized agent or by any other person responsible for placing the product on the 
Community market. 
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Directive 76/768/EEC will be replaced by a new Regulation (EC) No.1223/2009 (EC 
2009b) on cosmetic products which is not fully applicable until 11 July 2013. 
 
Annex I of Regulation (EC) No.1223/2009 specifies the minimum information which 
needs to be reported in the Cosmetic Product Safety Report. In relation to the requirements 
on the toxicological profile of the substances, Annex I explicitly mentions skin 
sensitisation as one of the toxicological endpoint necessitating particular focus together 
with local toxicity evaluation (skin and eye irritation) and photo-induced toxicity in case 
of UV absorption. More guidance is provided by the Scientific Committee on Consumer 
Safety (SCCS) in the "SCCS's Notes of Guidance for the Testing of Cosmetic Ingredients 
and their Safety Evaluation, 7th Revision" (EC 2010). The document provides guidance to 
public authorities and cosmetic industry, in order to improve harmonised compliance with 
Directive 76/768/EEC and in particular with the sixth (EU 1993) and the seventh (EC 
2003) amendments of this Directive. It also sets out the essential information required for 
safety files submitted for evaluation to the SCCS. According to the same guidance the risk 
assessment process for cosmetics ingredients should be conducted according to the 
following four steps: 
 
1) Hazard identification based on the results of in vivo tests, in vitro tests, 
clinical studies, accidents, human epidemiological studies and, when available, 
quantitative structure activity relationship (QSAR) studies. The intrinsic 
physical, chemical and toxicological properties of the molecule under 
consideration are studied to identify whether the substance has the potential to 
damage human health. 
 
2) Dose-response assessment in which the relationship between the toxic 
response and the exposure is studied. In the case of an effect with a threshold, 
the dosage at which No Adverse Effect Levels are observed (NOAEL), is 
determined. If the NOAEL is not available, the lowest dosage at which an 
adverse effect is observed (LOAEL) is used.  
 
3) Exposure assessment in which the amount and the frequency of human 
exposure to the compound are determined (including potential specific groups 
at risk, e.g. children, pregnant women, etc.). 
 
4) Risk characterisation: the probability that the substance under 
investigation causes damage to human health and the level of risk, are 
examined.  
 
Risk assessment for skin sensitisation relies on the above elements. The approaches 
currently used rely on a good understanding of the potency of the sensitiser. Such 
information is considered in the context of the ingredient’s concentration in the product 
and the predicted human exposure scenario.  
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The Cosmetics Directive and its 7th amendment introduce an end to animal testing by 
imposing bans on: 
 
 testing finished cosmetic products and ingredients on animals (testing ban); 
 marketing finished cosmetic products which have been tested on animals or 
which contain ingredients that have been tested on animals (marketing ban). 
 
The ban of animal testing of finished cosmetics product has been in force since September 
2004, whereas the animal testing ban of ingredients and combination of ingredients 
entered into force in March 2009. With regard to the marketing ban, this applies since 
March 2009 to all human health endpoints. In relation to tests concerning skin 
sensitisation, carcinogenicity, reproductive toxicity, repeated-dose toxicity and 
toxicokinetics, marketing ban will apply from March 2013 regardless of the availability of 
alternative test methods.  
 
As part of the implementation of the 2013 marketing ban, in 2011 the Commission had to 
report to the European Parliament and the Council in case alternatives to animal testing for 
the above mentioned human health effects will not be developed and validated by the 2013 
deadline. In that case the Commission shall elaborate a legislative proposal.  
 
Against this background, in 2010 the Commission invited scientific experts proposed by 
various stakeholders to review the state-of-play of alternative methods and to provide a 
science-based estimate of the time necessary to achieve full replacement of animal testing 
for the complex endpoints (Adler et al. 2011). For the area of skin sensitisation it was 
estimated that by 2017-2019 full replacement of animal tests might be achieved but that 
methods able to discriminate between sensitisers and non-sensitisers might become 
available earlier. 
 
Skin sensitisation represents an important endpoint for the consumer safety because of the 
high frequency of allergic reactions among the undesirable effects of cosmetic products. 
Accordingly, skin sensitisation represents the highest testing data need for the cosmetics 
sector with an average of 151 animal tests for skin sensitisation conducted per year by 
large companies and representing about 71% of the number of animal tests conducted per 
year for the 2013 endpoints (EC, 2011). 
 
It is important to note that 90% of ingredients used in cosmetics are being used in other 
areas (e.g. REACH, CLP, Biocidal Products etc.; (EC, 2011)). 
 
The information requirements described above for the five different pieces of legislations 
considered for the purpose of this report are summarised in Table 1. The same 
requirements are highlighted in Figure 3 concerning the timeline for the implementation of 
the different regulations. 
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Table 1: Overview of the EU legislations considered in the context of this report and their 
information requirements for skin sensitisation. 
 
EU 
Regulation/Directive Application Information requirements 
 
Method of choice 
 
CLP Regulation (EC) 
No 1272/2008 (for 
"Classification, 
Labelling and Packaging 
of substances and 
mixture” amending and 
repealing Directive 
67/548/EEC (Dangerous 
Substances Directive) 
and 1999/45/EC 
(Dangerous Preparations 
Directive). CLP is based 
on the Globally 
Harmonised System of 
Classification and 
Labelling of Chemicals 
(GHS) and is 
implementing the 
provisions of the GHS 
within the EU 
 
All substances and 
mixtures placed on the 
market irrespective of the 
tonnage level, fall within 
the scope of classification 
under CLP and should be 
evaluated in order to 
reach a decision as to 
whether they should be 
classified or not. All 
substances subject to 
REACH are also subject 
to classification, even 
those not placed on the 
market if they are subject 
to registration or 
notification. 
 
Hazard assessment and 
appropriate labelling 
 
Currently allows classification 
into one hazard category.  
Classification into potency 
categories is currently not a 
requirement in the classification of 
sensitisers even though expected 
to be introduced in a future 
amendment of CLP for complete 
implementation of GHS. 
Meanwhile for the application of 
the CLP criteria guidance is 
provided for refining the 
evaluation of skin sensitisers on 
the basis of their potency in the 
case this information is available.  
 
For new testing of 
substances the LLNA 
(TG 429) is now the 
method of first choice. In 
the exceptional 
circumstance that the 
LLNA is not appropriate, 
one of the alternative tests 
may be used (Buehler or 
guinea-pig Maximisation 
test (GPMT) (TG 406), 
but justification shall be 
provided. 
 
REACH Regulation 
(EC) No 1907/2006 
concerning the 
Registration, Evaluation, 
Authorization and 
Restriction of 
Chemicals. 
 
Skin sensitisation testing 
is mandatory for all 
substances manufactured 
or imported in the EU in 
quantities of one ton or 
more per year (lowest 
tonnage level) 
 
Considered to be the 
endpoint with the highest 
testing needs for phase-in 
substances. 
 
Hazard assessment  
 
Quantitative and/or qualitative 
risk characterisation is performed 
when potency information is 
available (from existing data or 
newly generated data) to refine the 
risk management measures and 
operational conditions and to 
derive a no-effect level (DNEL) to 
judge the residual likelihood of 
risk once such measures are 
implemented. 
 
For new testing of 
substances the LLNA 
(TG 429) is the method of 
first choice. In the 
exceptional circumstance 
that the LLNA is not 
appropriate, one of the 
alternative tests may be 
used (Buehler or GPMT), 
but justification shall be 
provided. 
 
PPP Regulation (EC) 
No 1107/2009 
concerning the placing 
of plant protection 
products on the market 
 
Regulation (EU) No 
544/2011implementing 
Regulation (EC) No 
1107/2009 of the 
European Parliament and 
of the Council as regards 
the data requirements for 
active substances 
 
PPP Regulation (EU) No 
545/2011 implementing 
Regulation (EC) No 
All plant protection 
products and active 
substances marketed in 
the EU independent of 
tonnage level 
 
Information requirement 
for skin sensitisation 
mandatory for both active 
substances contained in 
PPPs and the final 
product. 
 
Hazard assessment 
 
The test is not needed if the active 
substance is classified as a 
sensitiser according to Directive 
67/548/EEC or is otherwise 
known to be a sensitiser (from 
human data).  
 
The GPMT (TG 406) is 
considered to be the 
preferred adjuvant 
technique in certain cases 
there may be good 
reasons for choosing the 
Buehler test (TG 406) or 
the LLNA (TG 429). 
However, scientific 
justification may be given 
when either of the two 
latter tests is used. 
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1107/2009 of the 
European Parliament and 
of the Council as regards 
the data requirements for 
plant protection products 
(PPPs) 
Biocidals Directive 
(98/8/EC) concerning the 
placing of biocidal 
products on the market 
 
 
All biocidal products and 
active substances 
marketed in the EU 
independent of tonnage 
level 
 
Information requirement 
for skin sensitisation 
mandatory for both active 
substances contained in 
biocidal products and the 
final product. 
 
Hazard assessment 
 
The test is not needed if the active 
substance is classified as a 
sensitiser according to Directive 
67/548/EEC or is otherwise 
known to be a sensitiser (from 
human data).  
 
The GPMT (TG 406) is 
considered to be the 
preferred adjuvant 
technique in certain cases 
there may be good 
reasons for choosing the 
Buehler test (TG 406) or 
the LLNA (TG 429). 
However, scientific 
justification may be given 
when either of the two 
latter tests is used. 
Cosmetics Directive 
(76/768/EEC) and 7th  
Amendment (Directive  
2003/15/EC) 
 
All cosmetics ingredients 
independent of tonnage 
level. 
Skin senstisation is 
among the most relevant 
endpoints for the 
toxicological profile of 
cosmetics ingredient 
(considered to be the 
endpoint with the highest 
testing needs for the 
cosmetic sector) 
 
Information requirement 
for skin sensitisation 
included in the minimal 
base set requirement for 
inclusion of a substance 
in one of the Annexes to 
Directive 76/768/EEC. 
 
Hazard assessment + 
Quantitative risk 
characterisation 
 
All regulatory accepted 
test methods for skin 
sensitisation (LLNA, TG 
429; GPMT/BT TG 406). 
In practice the test of 
choice is the LLNA since 
it provides potency 
information. 
 
The ban on animal testing 
entered into force in 2009 
however until 2013 
industries will be allowed 
to place on the marked 
cosmetics containing 
ingredients tested on 
animals if testing was 
performed outside 
Europe. 
 
This will be no longer 
possible as from 2013 
when the marketing ban 
on cosmetics containing 
ingredients tested on 
animals will entry into 
force 
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Figure 3: Timeline for implementation of EU legislation and skin sensitisation 
information requirements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Regulatory Tests 
 
In the absence of validated alternative methods, regulatory accepted tests suitable to 
identify and characterise substances causing allergic contact dermatitis in humans rely on 
the use of animals. These include: the traditional guinea pig tests (Buehler Test and 
Guinea-pig Maximisation Test; OECD TG 406 (OECD 1992)) and the Local Lymph Node 
Assay (LLNA: OECD TG 429 (OECD 2010a)) including its non-radioactive variants 
(Local Lymph Node Assay: DA, OECD TG 442A (OECD 2010b) and Local Lymph Node 
Assay: BrdU Elisa, OECD TG 442B OECD (2010c)). The LLNA is considered a 
reduction/refinement method with respect to the traditional guinea-pig tests since it 
generally involves the use of fewer animals and entails less stressful procedures. The 
guinea-pig tests comprise both the induction phase and the elicitation phase of the immune 
response whereas the LLNA covers the mechanisms underlying the induction phase only. 
An overview of the regulatory accepted animal tests is provided in Table 2. 
 
 
 
 
 
 
1998  2009            2012 2013           2014         2015         2016         2017 2018         2019
BIOCIDES
DIRECTIVE
CLP 
REGULATION
PPP DIRECTIVE
COSMETICS DIRECTIVE: entry into
force of the marketing ban for the complex
endpoints including skin sensitisation. 
REACH: deadline for registration of
substances manufactured or imported at 100-
1000 tonnes/year.
Estimated that 1000 substances will require
skin sensitisation information.
CLP: likely implementation of mandatory
requirements for sub-categorisation of skin
sensitisers (1A,1B as defined by GHS).
NEW BIOCIDES REGULATION
REACH: deadline for registration of
substances manufactured or imported at 1-
100 tonnes/year.
Estimated that 10000 substances will
require skin sensitisation information.
Pieces of legislation requesting hazard
identification
Pieces of legislation requesting skin
sensitisers’ sub-categorisation
Pieces of legislation requesting skin
sensitisers’ potency information
NEW COSMETICS REGULATION
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Table 1: Overview of the regulatory accepted animal tests for skin sensitisation 
OECD Test 
Guidelines 
for Skin 
Sensitisation 
Skin 
sensitisation 
phases 
covered 
Animal 
species 
Adjuvant Exposure Dose levels No of 
animals in 
control/ 
treatment 
group 
Number 
of 
animals 
per test 
according 
to TG 
Test 
duration 
(days) 
Endpoint Classification criteria 
406: Guinea 
Pig 
Maximisation 
Test  
(GPMT)  
Induction +  
elicitation 
Guinea 
pig 
Yes  
(Freund’s 
Complete 
Adjuvant-
FCA) 
Induction: 
intradermal 
injections (day 0) 
and topical 
application (day 5-
7 and day 6-8) 
 
Challenge:  
topical application 
(day 20-22) by 
occluded patch 
 
Re-challenge: 
possible 
Induction:  
1 dose  (highest 
concentration to cause 
mild-to moderate-skin 
irritation) 
 
 
Challenge: 1 dose 
(highest non-irritant dose) 
10/20 30 23-25 Skin reactions 
(erythema/ 
oedema) 
Positive reaction in at least 
30% of the animals in the 
treatment group  
406: Buehler 
Test 
Induction +  
elicitation 
Guinea 
pig 
No Induction:  
topical application 
(day 0, day 6-8 and 
day 13-15) 
 
Challenge:  
topical application 
(day 27-29)  
 
Re-challenge: 
possible 
Induction: 1 dose  
(highest concentration to 
cause mild skin irritation) 
 
 
Challenge: 1 dose 
(highest non-irritant dose) 
10/20 30 30-32 Skin reactions 
(erythema/ 
oedema) 
Positive reaction in at least 
15% of the animals in the 
treatment group 
429: Local 
Lymph Node 
Assay 
Induction Mouse No Topical application At least 3 doses (highest 
dose should not give 
systemic toxicity and/or 
excessive local irritation) 
4/4 20 6 Cellular proliferation in 
auricular lymph nodes 
measured by radioactive 
labeling  
Stimulation Index (SI) >3 
at any dose. 
442A: Local 
Lymph Node 
Assay: DA 
Induction Mouse No 
Pre-
treatment 
with 1% 
Sodium 
Lauryl 
Sulphate 
(SLS) 
Topical application At least 3 doses (highest 
dose should not give 
systemic toxicity and/or 
excessive local irritation) 
4/4 20 8 Cellular proliferation in 
auricular lymph nodes 
quantified by 
determination of ATP 
content 
Stimulation Index (SI) ≥1.8 
at any dose. 
442B: Local 
Lymph Node 
Assay: BrdU 
Elisa 
Induction Mouse No Topical application At least 3 doses (highest 
dose should not give 
systemic toxicity and/or 
excessive local irritation) 
4/4 20 6 Cellular proliferation in 
auricular lymph nodes 
quantified by 
determination of BrdU 
incorporation 
Stimulation Index (SI) ≥1.6 
at any dose. 
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